Korsana Biosciences

Korsana Biosciences is a biotechnology company focused on developing next-generation treatments for metabolic diseases, including obesity and type 2 diabetes. The company leverages a proprietary peptide engineering platform to create long-acting multi-agonist therapies that target the GLP-1, GIP, and glucagon receptors. By optimizing the synergistic effects of these pathways, Korsana aims to achieve superior weight loss and metabolic improvements compared to existing mono- or dual-agonist treatments. The company is led by experts in peptide chemistry and metabolic research, including co-founder Richard DiMarchi. Korsana's approach focuses on maximizing efficacy while maintaining a favorable safety and tolerability profile for chronic administration.